ACB
Price
$2.79
Change
-$0.04 (-1.41%)
Updated
Jul 31 closing price
Capitalization
171.52M
2 days until earnings call
Intraday BUY SELL Signals
IMCC
Price
$0.12
Change
-$0.00 (-0.00%)
Updated
Jul 31 closing price
Capitalization
1.04M
Intraday BUY SELL Signals
Interact to see
Advertisement

ACB vs IMCC

ACB vs IMCC Comparison Chart in %
View a ticker or compare two or three
VS
ACB vs. IMCC commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and IMCC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (ACB: $2.79 vs. IMCC: $0.12)
Brand notoriety: ACB: Notable vs. IMCC: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 73% vs. IMCC: 12%
Market capitalization -- ACB: $171.52M vs. IMCC: $1.04M
ACB [@Pharmaceuticals: Generic] is valued at $171.52M. IMCC’s [@Pharmaceuticals: Generic] market capitalization is $1.04M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileIMCC’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • IMCC’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACB and IMCC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 4 TA indicator(s) are bullish while IMCC’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 4 bullish, 4 bearish.
  • IMCC’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, IMCC is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а +4.49% price change this week, while IMCC (@Pharmaceuticals: Generic) price change was -4.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.61%. For the same industry, the average monthly price growth was -5.02%, and the average quarterly price growth was +19.02%.

Reported Earning Dates

ACB is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($172M) has a higher market cap than IMCC($1.04M). ACB YTD gains are higher at: -33.886 vs. IMCC (-91.669). IMCC has higher annual earnings (EBITDA): -8.75M vs. ACB (-48.09M). ACB has more cash in the bank: 108M vs. IMCC (1M). IMCC has less debt than ACB: IMCC (15M) vs ACB (101M). ACB has higher revenues than IMCC: ACB (373M) vs IMCC (50.9M).
ACBIMCCACB / IMCC
Capitalization172M1.04M16,475%
EBITDA-48.09M-8.75M550%
Gain YTD-33.886-91.66937%
P/E Ratio19.44N/A-
Revenue373M50.9M733%
Total Cash108M1M10,757%
Total Debt101M15M673%
FUNDAMENTALS RATINGS
ACB vs IMCC: Fundamental Ratings
ACB
IMCC
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
7595
P/E GROWTH RATING
1..100
91100
SEASONALITY SCORE
1..100
3885

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMCC's Valuation (25) in the null industry is in the same range as ACB (42) in the Pharmaceuticals Other industry. This means that IMCC’s stock grew similarly to ACB’s over the last 12 months.

IMCC's Profit vs Risk Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that IMCC’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as IMCC (98) in the null industry. This means that ACB’s stock grew similarly to IMCC’s over the last 12 months.

ACB's Price Growth Rating (75) in the Pharmaceuticals Other industry is in the same range as IMCC (95) in the null industry. This means that ACB’s stock grew similarly to IMCC’s over the last 12 months.

ACB's P/E Growth Rating (91) in the Pharmaceuticals Other industry is in the same range as IMCC (100) in the null industry. This means that ACB’s stock grew similarly to IMCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBIMCC
RSI
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 20 days ago
85%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signal:
Gain/Loss:
IMCC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VREX11.190.12
+1.08%
Varex Imaging Corp
HTHT42.690.44
+1.04%
H World Group Limited
SEDG41.20-0.56
-1.34%
SolarEdge Technologies
OSTX1.52-0.04
-2.56%
OS Therapies Inc
NUWE1.74-2.71
-60.90%
Nuwellis Inc

IMCC and

Correlation & Price change

A.I.dvisor tells us that IMCC and ACB have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMCC and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMCC
1D Price
Change %
IMCC100%
+0.26%
ACB - IMCC
26%
Poorly correlated
-1.41%
TXMD - IMCC
25%
Poorly correlated
N/A
OGI - IMCC
24%
Poorly correlated
-2.96%
TRLV - IMCC
23%
Poorly correlated
+0.93%
CRON - IMCC
23%
Poorly correlated
-2.08%
More